Citigroup
OLMA icon

Citigroup’s Olema Pharmaceuticals OLMA Stock Holding History

Citigroup’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Buy
125,561
+97,983
+355% +$1.31M ﹤0.01% 3112
2026
Q1 		$411K Sell
27,578
-119,785
-81% -$2.67M ﹤0.01% 3658
2025
Q4 		$3.68M Buy
147,363
+126,917
+621% +$2.26M ﹤0.01% 2231
2025
Q3 		$200K Sell
20,446
-49,885
-71% -$300K ﹤0.01% 3995
2025
Q2 		$300K Buy
70,331
+39,340
+127% +$175K ﹤0.01% 3876
2025
Q1 		$117K Sell
30,991
-37,005
-54% -$186K ﹤0.01% 4511
2024
Q4 		$396K Buy
67,996
+37,899
+126% +$379K ﹤0.01% 3993
2024
Q3 		$359K Buy
30,097
+6,345
+27% +$81.1K ﹤0.01% 3944
2024
Q2 		$257K Sell
23,752
-226,230
-90% -$2.45M ﹤0.01% 3762
2024
Q1 		$2.83M Buy
249,982
+245,175
+5,100% +$3.16M ﹤0.01% 2140
2023
Q4 		$67.4K Buy
4,807
+4,792
+31,947% +$64.4K ﹤0.01% 4384
2023
Q3 		$186 Sell
15
-7,979
-100% -$81.3K ﹤0.01% 5329
2023
Q2 		$72.2K Sell
7,994
-1,918
-19% -$11.6K ﹤0.01% 4413
2023
Q1 		$34.4K Buy
+9,912
New +$40.4K ﹤0.01% 4362
2022
Q4 		– Sell
-1,196
Closed -$3K – 5904
2022
Q3 		$3K Sell
1,196
-466
-28% -$1.98K ﹤0.01% 5401
2022
Q2 		$7K Sell
1,662
-6,317
-79% -$20K ﹤0.01% 5506
2022
Q1 		$34K Sell
7,979
-289
-3% -$1.59K ﹤0.01% 4901
2021
Q4 		$77K Buy
8,268
+5,253
+174% +$109K ﹤0.01% 4862
2021
Q3 		$83K Buy
3,015
+297
+11% +$8.02K ﹤0.01% 4483
2021
Q2 		$76K Buy
2,718
+1,531
+129% +$43.6K ﹤0.01% 4627
2021
Q1 		$39K Sell
1,187
-5,725
-83% -$245K ﹤0.01% 4842
2020
Q4 		$332K Buy
+6,912
New +$324K ﹤0.01% 4577

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Citigroup's OLMA Position: Q2 2026 in Review

Citigroup increased its Olema Pharmaceuticals (OLMA) stake by 355% in Q2 2026, buying an estimated $1.31M and bringing the position to 125,561 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3112.

Citigroup first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. The position peaked at $3.68M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Citigroup held 125,561 shares of Olema Pharmaceuticals worth $1.57M as of Q2 2026.
  • Citigroup bought 97,983 Olema Pharmaceuticals shares in Q2 2026, an estimated $1.31M.
  • Olema Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3112 holding.
  • Citigroup first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Olema Pharmaceuticals position peaked at $3.68M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.